The Duke Clinical and Translational Science Institute in Kannapolis has launched the MURDOCK COPD Study. People who have smoked might qualify. Researchers will study the severity of smoking-related symptoms in 850 people and follow the progression of lung function and symptoms over five years.
Goal: This observational study will collect information on the current level of symptoms, as well as ability to breathe, treatment, and outcomes of patients with COPD (Chronic Obstructive Pulmonary Disease) and follow the progression of the disease over five years. The study will look at the correlation between a participant’s status at the beginning of the study and the progression of symptoms during the study period. COPD is a progressive disease that makes it hard to breathe. COPD is sometimes called chronic bronchitis or emphysema. Smoking is the most common cause.
Compensation: Offered throughout the five-year study.
Interested in enrolling? Read the requirements below and call 704-250-5861 or email email@example.com.
Principal Investigator: Dr. Scott Palmer
Co-Principal Investigator: Dr. Jamie Todd
Eligibility Requirements: People who qualify for this study are at least 40 years old; are current or former heavy smokers (tobacco exposure equal to or greater than the equivalent of smoking at least one pack a day for 10 years). They may or may not have COPD or emphysema.
Exclusion Criteria: People who are listed for a lung transplant and people who are participating in an investigational drug trial will not qualify for this study.
Study Requirements: People who qualify and choose to enroll in the study will be asked to complete a medical questionnaire to document smoking history; complete a physical activity questionnaire; walk for six minutes; and have their height and weight measured. During the five years of study follow-up, participants also will be asked to alternate between an in-person study visit and a telephone interview every six months. This study aims to follow participants for five years; however, participants can withdraw at any time. Compensation will be offered throughout the study.
Enrollment Goal: 850
Pro00011196, Pro00072667, Pro00074034